Distribution, function and physiological role of melatonin in the lower gut

World Journal of Gastroenterology

Volumn 17, Issue 34, 2011, Pages 3888-3898

  Chen, Chun Qiu ^a,b   Fichna, Jakub ^b   Bashashati, Mohammad ^b   Li, Yong Yu ^a   Storr, Martin ^b,c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CALGARY   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Clinical trial; Colon; Ileum; Inflammatory bowel disease; Melatonin; Motility; Receptor

Indexed keywords

MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN 3 RECEPTOR; MELATONIN RECEPTOR; UNCLASSIFIED DRUG;

COLON; DIGESTIVE SYSTEM INFLAMMATION; ENTERITIS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL PAIN; GASTROINTESTINAL TRACT; HORMONE RECEPTOR INTERACTION; HUMAN; ILEUM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PINEALECTOMY; RECTUM; REVIEW;

EID: 80054821679     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i34.3888     Document Type: Review

References (140)

1. Messner M, Huether G, Lorf T, Ramadori G,Schworer H. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-551
2. Bubenik GA. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59 Suppl 2: 33-51
3. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336: 186-195
4. Bubenik GA, Hacker RR, Brown GM, Bartos L. Melatonin concentrations in the luminal fluid, mucosa, and muscularis of the bovine and porcine gastrointestinal tract. J Pineal Res 1999; 26: 56-63
5. Hong GX, Pang SF. N-acetyltransferase activity in the quail (Coturnix coturnix jap) duodenum. Comp Biochem Physiol B Biochem Mol Biol 1995; 112: 251-255
6. Stefulj J, Hörtner M, Ghosh M, Schauenstein K, Rinner I, Wölfler A, Semmler J, Liebmann PM. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res 2001; 30: 243-247
7. Maldonado MD, Mora-Santos M, Naji L, Carrascosa-Salmoral MP, Naranjo MC, Calvo JR. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 2010; 62: 282-287
8. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001; 10: 467-476
9. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000; 28: 193-202
10. Bubenik GA, Brown GM, Bubenik AB, Grota LJ. Immunohistological localization of testosterone in the growing antler of the white-tailed deer (Odocoileus virginianus). Calcif Tissue Res 1974; 14: 121-130
11. Menendez-Pelaez A, Poeggeler B, Reiter RJ, Barlow-Walden L, Pablos MI, Tan DX. Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J Cell Biochem 1993; 53: 373-382
12. Poon AM, Chow PH, Mak AS, Pang SF. Autoradiographic localization of 2[125I]iodomelatonin binding sites in the gastrointestinal tract of mammals including humans and birds. J Pineal Res 1997; 23: 5-14
13. Bubenik GA. Localization of melatonin in the digestive tract of the rat. Effect of maturation, diurnal variation, melatonin treatment and pinealectomy. Horm Res 1980; 12: 313-323
14. Huether G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 1993; 49: 665-670
15. Kvetnoy IM, Ingel IE, Kvetnaia TV, Malinovskaya NK, Rapoport SI, Raikhlin NT, Trofimov AV, Yuzhakov VV. Gastrointestinal melatonin: cellular identification and biological role. Neuro Endocrinol Lett 2002; 23: 121-132
16. Huether G, Poeggeler B, Reimer A, George A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992; 51: 945-953
17. Huether G, Messner M, Rodenbeck A, Hardeland R. Effect of continuous melatonin infusions on steady-state plasma melatonin levels in rats under near physiological conditions. J Pineal Res 1998; 24: 146-151
18. Bubenik GA, Brown GM. Pinealectomy reduces melatonin levels in the serum but not in the gastrointestinal tract of rats. Biol Signals 1997; 6:40-44
19. Stebelová K, Herichová I, Zeman M. Diabetes induces changes in melatonin concentrations in peripheral tissues of rat. Neuro Endocrinol Lett 2007; 28: 159-165
20. Bubenik GA, Pang SF. The role of serotonin and melatonin in gastrointestinal physiology: ontogeny, regulation of food intake, and mutual serotonin-melatonin feedback. J Pineal Res 1994; 16: 91-99
21. Bertrand PP, Bertrand RL, Camello PJ, Pozo MJ. Simultaneous measurement of serotonin and melatonin from the intestine of old mice: the effects of daily melatonin supplementation. J Pineal Res 2010; 49: 23-34
22. Bubenik GA, Pang SF, Hacker RR, Smith PS. Melatonin concentrations in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food. J Pineal Res 1996; 21: 251-256
23. Bubenik GA, Ball RO, Pang SF. The effect of food deprivation on brain and gastrointestinal tissue levels of tryptophan, serotonin, 5-hydroxyindoleacetic acid, and melatonin. J Pineal Res 1992; 12: 7-16
24. Barrett P, Conway S, Morgan PJ. Digging deep--structure-function relationships in the melatonin receptor family. J Pineal Res 2003; 35: 221-230
25. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 1995; 16: 50-56
26. Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE 2001; 2001: pe39
27. Jockers R, Maurice P, Boutin JA, Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 2008; 154: 1182-1195
28. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 2002; 309: 151-162
29. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72: 2183-2198
30. Bondi CD, McKeon RM, Bennett JM, Ignatius PF, Brydon L, Jockers R, Melan MA, Witt-Enderby PA. MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation. J Pineal Res 2008; 44: 288-298
31. Chan ASL, Lai FPL, Lo RKH, Voyno-Yasenetskaya TA, Stanbridge EJ, Wong YH. Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002; 14:249-257
32. Ho MK, Yung LY, Chan JS, Chan JH, Wong CS, Wong YH. Galpha(14) links a variety of G(i)- and G(s)-coupled receptors to the stimulation of phospholipase C. Br J Pharmacol 2001; 132: 1431-1440
33. Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci 1996; 17: 100-102
34. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92: 8734-8738
35. Shiu SY, Ng N, Pang SF. A molecular perspective of the genetic relationships of G-protein coupled melatonin receptor subtypes. J Pineal Res 1996; 20: 198-204
36. Lucarini S, Bedini A, Spadoni G, Piersanti G. An improved synthesis of cis-4-phenyl-2-propionamidotetralin (4-P-PDOT): a selective MT(2) melatonin receptor antagonist. Org Biomol Chem 2008; 6: 147-150
37. Anisimov SV, Popovic N. Genetic aspects of melatonin biology. Rev Neurosci 2004; 15: 209-230
38. Zisapel N, Laudon M. Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: inhibition by melatonin. Biochem Biophys Res Commun 1982; 104: 1610-1616
39. Laudon M, Nir I, Zisapel N. Melatonin receptors in discrete brain areas of the male rat. Impact of aging on density and on circadian rhythmicity. Neuroendocrinology 1988; 48: 577-583
40. Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000; 917: 387-396
41. Hirose T, Smith RJ, Jetten AM. ROR gamma: the third member of ROR/RZR orphan receptor subfamily that is highly expressed in skeletal muscle. Biochem Biophys Res Commun 1994; 205: 1976-1983
42. Benítez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006; 40: 1-9
43. Macías M, Escames G, Leon J, Coto A, Sbihi Y, Osuna A, Acuña-Castroviejo D. Calreticulin-melatonin. An unexpected relationship. Eur J Biochem 2003; 270: 832-840
44. Meléndez J, Maldonado V, Ortega A. Effect of melatonin on beta-tubulin and MAP2 expression in NIE-115 cells. Neurochem Res 1996; 21: 653-658
45. Lee PP, Pang SF. Melatonin and its receptors in the gastrointestinal tract. Biol Signals 1993; 2: 181-193
46. Sallinen P, Saarela S, Ilves M, Vakkuri O, Leppäluoto J. The expression of MT1 and MT2 melatonin receptor mRNA in several rat tissues. Life Sci 2005; 76: 1123-1134
47. Soták M, Mrnka L, Pácha J. Heterogeneous expression of melatonin receptor MT1 mRNA in the rat intestine under control and fasting conditions. J Pineal Res 2006; 41: 183-188
48. Poirel VJ, Cailotto C, Streicher D, Pévet P, Masson-Pévet M, Gauer F. MT1 melatonin receptor mRNA tissular localization by PCR amplification. Neuro Endocrinol Lett 2003; 24: 33-38
49. Stebelová K, Anttila K, Mänttäri S, Saarela S, Zeman M. Immunohistochemical definition of MT(2) receptors and melatonin in the gastrointestinal tissues of rat. Acta Histochem 2010; 112: 26-33
50. Santagostino-Barbone MG, Masoero E, Spelta V, Lucchelli A. 2-Phenylmelatonin: a partial agonist at enteric melatonin receptors. Pharmacol Toxicol 2000; 87: 156-160
51. Nosjean O, Nicolas JP, Klupsch F, Delagrange P, Canet E, Boutin JA. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol 2001; 61: 1369-1379
52. Ting N, Thambyraja A, Sugden D, Scalbert E, Delagrange P, Wilson VG. Pharmacological studies on the inhibitory action of melatonin and putative melatonin analogues on porcine vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 327-333
53. Doolen S, Krause DN, Dubocovich ML, Duckles SP. Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 1998; 345: 67-69
54. Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol 2002; 23: 298-302
55. Aydin M, Canpolat S, Kuloǧlu T, Yasar A, Colakoglu N, Kelestimur H. Effects of pinealectomy and exogenous melatonin on ghrelin and peptide YY in gastrointestinal system and neuropeptide Y in hypothalamic arcuate nucleus: immunohistochemical studies in male rats. Regul Pept 2008; 146: 197-203
56. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17: 273-285
57. Konturek PC, Konturek SJ, Brzozowski T, Dembinski A, Zembala M, Mytar B, Hahn EG. Gastroprotective activity of melatonin and its precursor, L-tryptophan, against stress-induced and ischaemia-induced lesions is mediated by scavenge of oxygen radicals. Scand J Gastroenterol 1997; 32: 433-438
58. Schultz CL, Edrington TS, Callaway TR, Schroeder SB, Hallford DM, Genovese KJ, Anderson RC, Nisbet DJ. The influence of melatonin on growth of E. coli O157: H7 in pure culture and exogenous melatonin on faecal shedding of E. coli O157: H7 in experimentally infected wethers. Lett Appl Microbiol 2006; 43: 105-110
59. Lucchelli A, Santagostino-Barbone MG, Tonini M. Investigation into the contractile response of melatonin in the guinea-pig isolated proximal colon: the role of 5-HT4 and melatonin receptors. Br J Pharmacol 1997; 121: 1775-1781
60. Storr M, Schusdziarra V, Allescher HD. Inhibition of small conductance K+ -channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus. Can J Physiol Pharmacol 2000; 78: 799-806
61. Harlow HJ, Weekley BL. Effect of melatonin on the force of spontaneous contractions of in vitro rat small and large intestine. J Pineal Res 1986; 3: 277-284
62. Drago F, Macauda S, Salehi S. Small doses of melatonin increase intestinal motility in rats. Dig Dis Sci 2002; 47: 1969-1974
63. Merle A, Delagrange P, Renard P, Lesieur D, Cuber JC, Roche M, Pellissier S. Effect of melatonin on motility pattern of small intestine in rats and its inhibition by melatonin receptor antagonist S 22153. J Pineal Res 2000; 29: 116-124
64. Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, Schusdziarra V, Allescher HD. Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J Pineal Res 2002; 33: 101-108
65. Barajas-López C, Peres AL, Espinosa-Luna R, Reyes-Vázquez C, Prieto-Gómez B. Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucous plexus. Eur J Pharmacol 1996; 312: 319-325
66. Reyes-Vázquez C, Naranjo-Rodríguez EB, García-Segoviano JA, Trujillo-Santana JT, Prieto-Gómez B. Apamin blocks the direct relaxant effect of melatonin on rat ileal smooth muscle. J Pineal Res 1997; 22: 1-8
67. Velarde E, Alonso-Gómez AL, Azpeleta C, Isorna E, Delgado MJ. Melatonin attenuates the acetylcholine-induced contraction in isolated intestine of a teleost fish. J Comp Physiol B 2009; 179: 951-959
68. De Filippis D, Iuvone T, Esposito G, Steardo L, Arnold GH, Paul AP, De Man Joris G, De Winter Benedicte Y. Melatonin reverses lipopolysaccharide-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. J Pineal Res 2008; 44: 45-51
69. Bonouali-Pellissier S. Melatonin is involved in cholecystokinin-induced changes of ileal motility in rats. J Pineal Res 1994; 17: 79-85
70. Kasimay O, Cakir B, Devseren E, Yegen BC. Exogenous melatonin delays gastric emptying rate in rats: role of CCK2 and 5-HT3 receptors. J Physiol Pharmacol 2005; 56: 543-553
71. Velarde E, Delgado MJ, Alonso-Gómez AL. Serotonin-induced contraction in isolated intestine from a teleost fish (Carassius auratus): characterization and interactions with melatonin. Neurogastroenterol Motil 2010; 22: e364-e373
72. Matheus N, Mendoza C, Iceta R, Mesonero JE, Alcalde AI. Melatonin inhibits serotonin transporter activity in intestinal epithelial cells. J Pineal Res 2010; 48: 332-339
73. Cuzzocrea S, Mazzon E, Serraino I, Lepore V, Terranova ML, Ciccolo A, Caputi AP. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001; 30: 1-12
74. Chan HC, Lui KM, Wong WS, Poon AM. Effect of melatonin on chloride secretion by human colonic T84 cells. Life Sci 1998; 62: 2151-2158
75. Mrnka L, Hock M, Rybová M, Pácha J. Melatonin inhibits prostaglandin E2- and sodium nitroprusside-induced ion secretion in rat distal colon. Eur J Pharmacol 2008; 581: 164-170
76. Raghavendra V, Singh V, Kulkarni SK, Agrewala JN. Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. Mol Cell Biochem 2001; 221: 57-62
77. Shaji AV, Kulkarni SK, Agrewala JN. Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin-specific T cells. Clin Exp Immunol 1998; 111: 181-185
78. Lardone PJ, Rubio A, Cerrillo I, Gómez-Corvera A, Carrillo-Vico A, Sanchez-Hidalgo M, Guerrero JM, Fernandez-Riejos P, Sanchez-Margalet V, Molinero P. Blocking of melatonin synthesis and MT(1) receptor impairs the activation of Jurkat T cells. Cell Mol Life Sci 2010; 67: 3163-3172
79. García-Mauriño S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 2000; 29: 129-137
80. Pedrosa AM, Weinlich R, Mognol GP, Robbs BK, Viola JP, Campa A, Amarante-Mendes GP. Melatonin protects CD4+ T cells from activation-induced cell death by blocking NFAT-mediated CD95 ligand upregulation. J Immunol 2010; 184: 3487-3494
81. Szczepanik M. Melatonin and its influence on immune system. J Physiol Pharmacol 2007; 58 Suppl 6: 115-124
82. Maestroni GJ, Sulli A, Pizzorni C, Villaggio B, Cutolo M. Melatonin in rheumatoid arthritis: synovial macrophages show melatonin receptors. Ann N Y Acad Sci 2002; 966: 271-275
83. Lardone PJ, Carrillo-Vico A, Molinero P, Rubio A, Guerrero JM. A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: significance in IL-2 production. Cell Mol Life Sci 2009; 66: 516-525
84. Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernández-Montesinos R, Guerrero JM, Pozo D. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs 2006; 7: 423-431
85. Drazen DL, Nelson RJ. Melatonin receptor subtype MT2 (Mel 1b) and not mt1 (Mel 1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2001; 74: 178-184
86. Carrillo-Vico A, Lardone PJ, Fernández-Santos JM, Martín-Lacave I, Calvo JR, Karasek M, Guerrero JM. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J Clin Endocrinol Metab 2005; 90: 992-1000
87. Ercan F, Cetinel S, Contuk G, Cikler E, Sener G. Role of melatonin in reducing water avoidance stress-induced degeneration of the gastrointestinal mucosa. J Pineal Res 2004; 37: 113-121
88. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200
89. Pentney PT, Bubenik GA. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res 1995; 19: 31-39
90. Nosál'ová V, Zeman M, Cerná S, Navarová J, Zakálová M. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res 2007; 42: 364-370
91. Esposito E, Mazzon E, Riccardi L, Caminiti R, Meli R, Cuzzocrea S. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 2008; 45: 166-173
92. Dong WG, Mei Q, Yu JP, Xu JM, Xiang L, Xu Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 2003; 9: 1307-1311
93. Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J, Luo HS. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm 2005; 2005: 185-193
94. Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res 2006; 40: 168-176
95. Necefli A, Tulumoǧlu B, Giriş M, Barbaros U, Gündüz M, Olgaç V, Güloǧlu R, Toker G. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci 2006; 51: 1538-1545
96. Mei Q, Yu JP, Xu JM, Wei W, Xiang L, Yue L. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 2002; 23: 882-886
97. Akcan A, Kucuk C, Sozuer E, Esel D, Akyildiz H, Akgun H, Muhtaroglu S, Aritas Y. Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J Gastroenterol 2008; 14: 918-924
98. Mazzon E, Esposito E, Crisafulli C, Riccardi L, Muià C, Di Bella P, Meli R, Cuzzocrea S. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006; 41: 363-373
99. Marquez E, Sánchez-Fidalgo S, Calvo JR, la de Lastra CA, Motilva V. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J Pineal Res 2006; 40: 48-55
100. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2: 167-179
101. Konturek SJ, Konturek PC, Brzozowska I, Pawlik M, Sliwowski Z, Cześnikiewicz-Guzik M, Kwiecień S, Brzozowski T, Bubenik GA, Pawlik WW. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol 2007; 58: 381-405
102. Radwan P, Skrzydlo-Radomanska B, Radwan-Kwiatek K, Burak-Czapiuk B, Strzemecka J. Is melatonin involved in the irritable bowel syndrome? J Physiol Pharmacol 2009; 60 Suppl 3: 67-70
103. Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L. Melatonin and serotonin effects on gastrointestinal motility. J Physiol Pharmacol 2007; 58 Suppl 6: 97-103
104. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-2348
105. Maestroni GJ. The immunoneuroendocrine role of melato nin. J Pineal Res 1993; 14: 1-10
106. Mickle A, Sood M, Zhang Z, Shahmohammadi G, Sengupta JN, Miranda A. Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process. Pain 2010; 149: 555-564
107. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-1407
108. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005; 22: 927-934
109. Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007; 41: 29-32
110. Lu WZ, Song GH, Gwee KA, Ho KY. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci 2009; 54: 1087-1093
111. Jan JE, Freeman RD. Re: Mann--melatonin for ulcerative colitis? Am J Gastroenterol 2003; 98: 1446
112. Mann S. Melatonin for ulcerative colitis? Am J Gastroenterol 2003; 98: 232-233
113. Maldonado MD, Calvo JR. Melatonin usage in ulcerative colitis: a case report. J Pineal Res 2008; 45: 339-340
114. Calvo JR, Guerrero JM, Osuna C, Molinero P, Carrillo-Vico A. Melatonin triggers Crohn's disease symptoms. J Pineal Res 2002; 32: 277-278
115. Poon AM, Mak AS, Luk HT. Melatonin and 2[125I]iodome-latonin binding sites in the human colon. Endocr Res 1996; 22: 77-94
116. Kos-Kudla B, Ostrowska Z, Kozlowski A, Marek B, Ciesielska-Kopacz N, Kudla M, Kajdaniuk D, Strzelczyk J, Staszewicz P. Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuro Endocrinol Lett 2002; 23: 239-242
117. Hrushesky WJ, Grutsch J, Wood P, Yang X, Oh EY, Ansell C, Kidder S, Ferrans C, Quiton DF, Reynolds J, Du-Quiton J, Levin R, Lis C, Braun D. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther 2009; 8: 387-397
118. Dalio MB, Haikel Júnior LF, Dalio RB, Pinto AP, Silva JC, Vespúcio MV, Guimarães MA, Garcia SB. A study of the effects of pinealectomy on intestinal cell proliferation in infant newborn rats. Acta Cir Bras 2006; 21: 16-20
119. Callaghan BD. The long-term effect of pinealectomy on the crypts of the rat gastrointestinal tract. J Pineal Res 1995; 18: 191-196
120. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 2001; 22: 45-47
121. Blask DE, Wilson ST, Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res 1997; 57: 1909-1914
122. Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-24
123. Panzer A, Viljoen M. The validity of melatonin as an oncostatic agent. J Pineal Res 1997; 22: 184-202
124. Wenzel U, Nickel A, Daniel H. Melatonin potentiates flavone-induced apoptosis in human colon cancer cells by increasing the level of glycolytic end products. Int J Cancer 2005; 116: 236-242
125. García-Navarro A, González-Puga C, Escames G, López LC, López A, López-Cantarero M, Camacho E, Espinosa A, Gallo MA, Acuña-Castroviejo D. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205
126. Karasek M, Carrillo-Vico A, Guerrero JM, Winczyk K, Pawlikowski M. Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer. Neuro Endocrinol Lett 2002; 23 Suppl 1: 55-60
127. Winczyk K, Fuss-Chmielewska J, Lawnicka H, Pawlikowski M, Karasek M. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. Neuro Endocrinol Lett 2009; 30: 657-662
128. Ravindra T, Lakshmi NK, Ahuja YR. Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci 2006; 60: 523-535
129. Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T, Rahman KM. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009; 177: 128-136
130. Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol 2006; 87: 81-87
131. Martins E, Fernandes LC, Bartol I, Cipolla-Neto J, Costa Rosa LF. The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumour-bearing rats. J Neuroimmunol 1998; 82: 81-89
132. Lissoni P, Barni S, Tancini G, Rovelli F, Ardizzoia A, Conti A, Maestroni GJ. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology 1993; 50: 399-402
133. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 2007; 55: 201-204
134. Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35: 1688-1692
135. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 2003; 23: 1951-1954
136. Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994; 69: 196-199
137. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, Fumagalli L, Brivio F, Tancini G. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995; 52: 243-245
138. Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun 1998; 16: 27-33
139. Persson C, Glimelius B, Rönnelid J, Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 2005; 21: 170-178
140. Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo 2008; 22: 397-400